Coeptis Therapeutics, Inc.
NASDAQ:COEPBiotechnology
+$0.73 today
- Market cap
- $57.63M
- Beta
- -0.43
- P/E (TTM)
- -8.3
- EPS (TTM)
- -$1.97
Volume 0.18M
Average 0.05M
COEP Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
Coeptis Therapeutics, Inc.NASDAQ: COEP
Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026
Cash & equivalents rises 22.1% from a year ago
Cash & equivalents stood at $5.21M at the end of Q1 FY2026, up 22.1% from a year earlier and down 8.2% from the prior quarter. Over 3 fiscal years it compounded at +14.4% a year.
Context
- Cash & equivalents amounted to 26.3% of total assets at the end of Q1 FY2026, down 5.4 pp from a year earlier.
- Cash & equivalents increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +22.1% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 5.67M USD
- Year-over-year change
- +964.8%
- 4-year CAGR
- +27.0%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 5.67M | +964.8% |
| FY2024 | 2024-12-31 | 532.89K | -63.7% |
| FY2023 | 2023-12-31 | 1.47M | -61.2% |
| FY2022 | 2022-12-31 | 3.79M | +73.9% |
| FY2021 | 2021-12-31 | 2.18M | — |
Cash & Equivalents vs competitors
How COEP compares with its peers on the latest reported figures
- COEP's Mar 2026 cash & equivalents of $5.21M is the lowest of the 9 companies compared; the peer median is $33.71M.
- Its year-over-year change of +22.1% is the 6th highest of 9, against a peer median of +79.5%.
- Cash & equivalents amounts to 26.3% of total assets for COEP, versus a peer median of 62.8%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
OSTXOS Therapies Incorporated | Mar 2026 | $917.55M | +30783.5% | +1063.1% | 12570.5% |
| Mar 2026 | $90.85M | +134.3% | -23.5% | 69.1% | |
| Mar 2026 | $61.32M | +322.9% | -20.0% | 97.2% | |
| Mar 2026 | $51.05M | -1.6% | -9.8% | 15.6% | |
| Mar 2026 | $16.38M | +24.7% | -19.3% | 53.0% | |
| Mar 2026 | $7.75M | +2.5% | -22.5% | 35.4% | |
| Mar 2026 | $6.71M | +21.0% | -27.0% | 56.4% | |
| Mar 2026 | $5.56M | +1279.8% | +1625.2% | 96.0% | |
| Mar 2026 | $5.21M | +22.1% | +14.4% | 26.3% | |
| Peer median (excluding COEP) | $33.71M | +79.5% | -19.6% | 62.8% | |
Competitors are the stored peer set for COEP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 2.18M | 3.79M | 1.47M | 532.89K | 5.67M |
| Short-term Investments | 0 | 0 | 0 | 0 | 676.6K |
| Net Receivables | 0 | 8.08K | 38.98K | 0 | 7.35K |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | 2.18M | 3.94M | 1.75M | 1.05M | 7.35M |
| Property, Plant & Equipment (Net) | 31.85K | 71.46K | 108.88K | 59.78K | 18.4K |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 4.55M | 3.55M | 2.55M | 541.88K | 361.25K |
| Long-term Investments | 0 | 0 | 3.5M | 5.69M | 7.86M |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 4.55M | 348.33K | 158.33K | 1.56M | 4.25M |
| Total Non-current Assets | 4.59M | 3.97M | 6.32M | 7.86M | 12.49M |
| Total Assets | 6.77M | 7.92M | 8.07M | 8.91M | 19.84M |
| Account Payables | 134.09K | 99.02K | 1.42M | 1.27M | 888.76K |
| Short-term Debt | 2.42M | 1.89M | 1.01M | 1.19M | 118.88K |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 599.46K |
| Other Current Liabilities | 199.13K | 182K | 555.95K | 1.28M | 161.05K |
| Total Current Liabilities | 2.76M | 2.17M | 2.99M | 4.51M | 1.77M |
| Long-term Debt | 1.65M | 150K | 150K | 150K | 150K |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 1.13M | 557.25K | 359.25K | 167.63K |
| Total Non-current Liabilities | 1.65M | 1.29M | 768.43K | 528.13K | 317.63K |
| Total Liabilities | 4.41M | 3.46M | 3.76M | 5.04M | 2.09M |
| Common Stock | 3.55K | 1.96K | 3.53K | 212 | 575 |
| Retained Earnings | (27.55M) | (66.09M) | (87.36M) | (98.23M) | (109.95M) |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 |
| Other Stockholders Equity | 0 | 0 | 0 | (1.56M) | 0 |
| Minority Interest | 0 | 0 | 0 | 682.06K | 506.16K |
| Total Equity | 2.35M | 4.45M | 4.31M | 3.87M | 17.75M |
| Total Debt | 4.08M | 2.06M | 1.22M | 1.4M | 268.88K |
| Net Debt | 1.9M | (1.73M) | (244.91K) | 866.17K | (5.41M) |
Coeptis Therapeutics, Inc.
NASDAQ:COEP
Intrinsic Alpha fair value
Locked
Current Price
$14.64
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.